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In 1673, William Harvey wrote that ‘the heart is to 
be regarded as the primary cause of life’.[1] In 1705, 
Thomas Sydenham, an English physician, linked 
dropsy to difficulty in breathing,[2] marking the 
beginnings of the concept of heart failure (HF) for 
which digitalis, described by Withering in 1801, was the first natural 
remedy to be used.[3] Withering was most impressed with its diuretic 
effects, but he also observed that ‘digitalis had power over the motion 
of the heart to a degree, yet unobserved in any other medicine’. 
Despite this auspicious history, the use of digoxin is now in serious 
question as shown by the most recent largest and longest study, from 
Quebec, in which digoxin  use over 14 years was associated with a 
14% greater risk of all-cause mortality in patients aged ≥65 years with 
atrial fibrillation (AF) regardless of concomitant HF.[4] The present 
article, and other reports since digoxin therapy was last reviewed in 
the SAMJ in 2011,[5] forcefully bring to our attention that the decision 
to treat with digoxin potentially exposes the patient to serious risks 
such as drug toxicity and even death,[4] as also shown in a recent study 
on American veterans.[6]
Swings in digitalis use
Digitalis has gone through several phases. Historically it has been 
long regarded as essential first-line therapy for HF, together with 
the diuretics. As data on ineffectiveness or tolerance came in, its 
use declined, especially in the UK. Thereafter use declined again 
for several reasons, the first of which was that there were no recent 
studies to eliminate major doubts regarding the ideal dose and blood 
levels.[4-6] Even in the large Digitalis Investigation Group (DIG) 
trial in 1997, when HF therapy was relatively primitive and did 
not have the benefit of beta-blockade and angiotensin-converting 
enzyme inhibitors, there were only limited benefits.[7] Thereafter, 
positive haemodynamic data in several small studies and the major 
withdrawal studies re-established the reputation of digoxin, but that 
was 21 years ago.[8] Currently the declining use relates in part to the 
increasing realisation that digoxin is a very complex drug with a very 
narrow therapeutic-toxic window and numerous drug interactions 
(see Tables 6-6 and 6-7 in Teerlink et al.[9]).
These many problems have relegated digoxin to an optional extra 
in the management of heart failure, given, if at all, in lower doses 
than previously, with the aim of achieving symptomatic rather than 
mortality benefit.
Digoxin kinetics, toxicity and 
contraindications
Digoxin is rapidly absorbed into the circulation where it is unbound 
to plasma proteins, with a therapeutic level of 0.65 - 1.3 nmol/L, 
which is about half of the previous toxic level as shown in Fig. 6-12 in 
Teerlink et al.[9] Also of note, is the role of the plasma potassium level 
in the expression of digoxin toxicity, whereby low potassium levels 
sensitise the heart to the prevailing digoxin level. The blood half-life 
is about 36 hours. About 70% is excreted unchanged in the urine 
after tubular excretion, with the remainder undergoing non-renal 
clearance by the liver and in the stools.[9]
In brief, toxicity and major contraindications are as follows:
• Digitalis toxicity is the major complication, pending a full history 
of digitalis dosage, blood tests for renal failure, and measurement 
of serum digoxin and potassium. Digoxin has a blood half-life of 
36 hours, so toxicity is not readily reversed and requires digoxin 
antibodies which are not widely available.
• Hypertrophic obstructive cardiomyopathy
• Some cases of Wolff-Parkinson-White syndrome
• Atrioventricular nodal heart block if significant.
Recent studies
There are four recent studies, of which the largest and the most 
recent in clinical practice, in Quebec, showed that digoxin use over 
14 years was associated with a 14% greater risk of all-cause mortality 
in patients aged ≥65 years with AF, regardless of concomitant HF.[10] 
This study reached the public arena via the New York Times, which 
reported on 8 August 2014 that ‘the investigators followed more 
than 100,000 people with newly diagnosed AF and found that those 
prescribed digoxin were more likely to die over the next several years 
than those who received other treatments’.[11] Further population 
studies may never be undertaken owing to lack of funding and lack 
of urgency.
The three other recent reports are of note.[12-14] In the first, the 
authors identified adults with incident systolic HF between 2006 
and 2008 within the Kaiser Permanente Northern California group 
who had no prior digoxin use.[12] The important result was that 
digoxin use, during a median 2.5 years of follow-up in 2 891 patients 
with incident systolic HF, was independently associated with an 
increased risk of death (hazard ratio 1.72; 95% confidence interval 
1.25 - 2.36), although there was no difference in HF hospitalisation. 
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The researchers had controlled for medical history, laboratory results, 
medications, HF disease severity, and the propensity for digoxin use 
in their patient population.
Digoxin to control ventricular 
rate in HF
Even those authorities who still hold that there a place for digoxin 
in HF therapy[15] admit that the place of digoxin in AF is insecure 
and will probably diminish further in the future, because of the 
drug’s inability to reduce heart rate during exercise on the one hand, 
and the outcome of studies such as the defective negative study of 
Whitbeck et al.[13] on the other.
Regarding the other major use of digoxin to control the heart rate 
in HF, in a recent single-centre study on 1 269 unselected consecutive 
patients with both AF and HF, therapy with a beta-blocker alone or 
with a beta-blocker plus digoxin was associated with a similar decrease 
of just over 40% in risk of death (p=0.005).[16] Of further note, digoxin 
given alone was associated with a worse survival probability, similar to 
that of patients without any rate control treatment.
Conclusions
There are very few arguments left in favour of the use of digitalis 
in the control of heart rate in AF. After the negative mortality data 
from one large recent study of digitalis in HF, enthusiasm for its 
further testing in HF has diminished further. Ideally an even larger, 
multicentre, prospective randomised controlled trial could add new 
conclusive data. Such a trial is, however, very unlikely to be done 
in view of the low likelihood of digoxin’s finding a prominent place 
in the current increasingly sophisticated therapy of HF.[9] In the 
absence of such a trial, it would be safe to predict that digoxin for the 
indication of HF would not be passed by regulatory agencies on the 
basis of present data.
1. Willis R. The Works of William Harvey MD. London: Sydenham Society, 1847.
2. Sydenham T. The Whole Works. London, 1705.
3. Wilkins MR, Kendall MJ, Wade OL. William Withering and digitalis, 1785 to 1985. BMJ
1985;290(6461):7-8.
4. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Behlouli H, Pilote L. Relation of  digoxin  use 
in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without 
heart failure. Am J Cardiol 2014;114(3):401-406. [http://dx.doi.org/10.1016/j.amjcard.2014.05.013]
5. Opie LH. Dilated cardiomyopathy and potentially deadly digoxin. S Afr Med J 2011;101(6):388-390.
6. Georgiopoulou VV, Kalogeropoulos AP, Giamouzis G, et al. Digoxin therapy does not improve
outcomes in patients with advanced heart failure on contemporary medical therapy. Circ Heart Fail 
2009;2:90-97. [http://dx.doi.org/10.1161/CIRCHEARTFAILURE.108.807032]
7. Dec GW. Digoxin remains useful in the management of chronic heart failure. Med Clin North
Am 2003;87(2):317-337.
8. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with 
heart failure. N Engl J Med 1997;336(80):525-533.
9. Teerlink JR, Sliwa K, Opie LH. Heart failure. In: Opie LH, Gersh BJ. Drugs for the Heart. 8th ed. 
Philadelphia: Elsevier Saunders, 2013:169-223.
10. Shah M, Tsadok MA, Jackevicius CA, Essebag V, Behlouli H, Pilote L. Relation of digoxin use in atrial 
fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart 
failure. Am J Cardiol 2014;114(3):401-406. [http://dx.doi.org/10.1016/j.amjcard.2014.05.013]
11. Digoxin tied to increased risk of death in new atrial fibrillation patients. New York Times (8/11, D4, 
O’Connor).
12. Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among
contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes
2013;6(5):525-533. [http://dx.doi.org/10.1161/CIRCOUTCOMES.111.000079]
13. Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin –
analysis from the AFFIRM study. Eur Heart J  2013;34(20):1481-1488. [http://dx.doi.org/10.1093/
eurheartj/ehs348]
14. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, et al Lack of evidence of increased mortality among 
patients with atrial fibrillation taking digoxin: Findings from post hoc propensity-matched analysis of 
the AFFIRM trial. Eur Heart J 2013;34(20):1489-1497. [http://dx.doi.org/10.1093/eurheartj/eht120]
15. Van Veldhuisen DJ, van Gelder IC, Ali A, Gheorghiade M. Digoxin for patients with atrial fibrillation 
and heart failure: Paradise lost or not? Eur Heart J 2013;34(20):1468-1470. [http://dx.doi.org/10.1093/
eurheartj/ehs483]
16. Fauchier L, Grimard C, Nonin P, et al. Comparison of beta blocker and digoxin alone and in
combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol 
2009;103(2):248-254. [http://dx.doi.org/10.1016/j.amjcard.2008.09.064]
Accepted 8 September 2014.
